Wordt geladen...
Radioimmunotherapy in Non-Hodgkin’s Lymphoma: Retrospective Adverse Event Profiling of Zevalin and Bexxar
The development of monoclonal antibodies has dramatically changed the outcome of patients with non-Hodgkin’s lymphoma (NHL), the most common hematological malignancy. However, despite the satisfying results of monoclonal antibody treatment, only few NHL patients are permanently cured with single-age...
Bewaard in:
| Gepubliceerd in: | Pharmaceuticals (Basel) |
|---|---|
| Hoofdauteurs: | , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
MDPI
2019
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6958320/ https://ncbi.nlm.nih.gov/pubmed/31546999 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph12040141 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|